PYPD PolyPid Total Debt to Capital

This price chart illustrates the financial leverage of PolyPid Ltd. (PYPD), which currently stands at 0.31. The business relies on the development of sustained-release antibiotic systems, distributing tests across various operations to minimize risk. PLEX technology is protected by patents and strict FDA regulations, which block the entry of generics. The development of new agents is accelerating through close collaboration with specialized clinics.

This indicator measures the proportion of borrowed funds relative to equity, determining the degree of financial leverage and the business's ability to service its obligations. For PolyPid Ltd. during the commercial scaling of its platform in the US, the financial risk metric (debt-to-equity) is critical, as it demonstrates the stability of the financing structure during the transition to active sales, eliminating the risk of a debt trap.